ASCO 2021 -Sanofi, Incyte, Exelixis, and

Quote

anonymous

Guest
AstraZeneca plans to present more than 100 abstracts featuring 21 approved and pipeline drugs from its oncology portfolio. Four of the abstracts were chosen as late-breakers. There are 12 oral presentations and one plenary presentation.

Then there’s GSK. Two weeks before ASCO and it crickets. Am I missing something here?
 






I think we all know the answer... there isn’t much to be excited about. Lots of stuff way out and no new acquisitions so I guess we can present blenrep and zejula again.
 






No innovation, no excitement, no interest from investigators in working with a company that sold oncology for a bag of beans to Novartis. Witty went off in the sunset with a multimillion pound package.
 












Top Bottom
Back
Quote